Luminex Corp (LMNX)

20.42
0.22 1.09
NASDAQ : Health Care
Prev Close 20.20
Open 20.24
Day Low/High 20.09 / 20.44
52 Wk Low/High 16.16 / 22.85
Volume 217.52K
Avg Volume 245.60K
Exchange NASDAQ
Shares Outstanding 43.93M
Market Cap 890.82M
EPS 0.30
P/E Ratio 84.50
Div & Yield 0.24 (1.20%)

Latest News

LMNX Crosses Above Average Analyst Target

LMNX Crosses Above Average Analyst Target

In recent trading, shares of Luminex Corp have crossed above the average analyst 12-month target price of $19.25, changing hands for $20.23/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Luminex Corporation Receives FDA Clearance For ARIES Bordetella Assay

Luminex Corporation Receives FDA Clearance For ARIES Bordetella Assay

Sample to answer assay provides accurate pertussis surveillance of clinically symptomatic patients

Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals

Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals

Luminex, Exelixis, AMAG Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.

Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More

Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More

Here are Friday's top research calls, including upgrades for IberiaBank and Actuant, and downgrades for Kimberly-Clark and Ionis Pharma.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABT, HIHO, KE, LBRDA, SSP, TLRD, VIV Downgrades: CORE, LMNX, PKOH, SIM, TATT, TTEC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Toll Brothers and Luminex Initiate Dividends

In each case, the start of cash payouts follows better-than-expected quarterly results.

Relative Strength Alert For Luminex

Relative Strength Alert For Luminex

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

LMNX: Insiders vs. Shorts

LMNX: Insiders vs. Shorts

The most recent short interest data was recently released for the 01/13/2017 settlement date, and Luminex Corp is one of the most shorted stocks of the Russell 3000, based on 11.24 "days to cover" versus the median component at 5.04. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Luminex Corporation Receives FDA Clearance For ARIES® GBS Assay

Luminex Corporation Receives FDA Clearance For ARIES® GBS Assay

Sample to answer GBS assay offers higher sensitivity and specificity compared to culture

LMNX: Insiders vs. Shorts

LMNX: Insiders vs. Shorts

The most recent short interest data was recently released for the 10/14/2016 settlement date, and Luminex Corp is one of the most shorted stocks of the Russell 3000, based on 16.32 "days to cover" versus the median component at 6.24. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Oversold Conditions For Luminex (LMNX)

Oversold Conditions For Luminex (LMNX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

LMNX Crosses Above Average Analyst Target

LMNX Crosses Above Average Analyst Target

In recent trading, shares of Luminex Corp have crossed above the average analyst 12-month target price of $21.67, changing hands for $21.95/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Luminex Stock Sees Short Interest Fall 10.7%

Luminex Stock Sees Short Interest Fall 10.7%

The most recent short interest data has been released for the 09/30/2016 settlement date, which shows a 338,203 share decrease in total short interest for Luminex Corp , to 2,811,935, a decrease of 10.74% since 09/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

How to Cash in on the Fight Against the Zika Virus

How to Cash in on the Fight Against the Zika Virus

Where some see danger and upheaval, investors see opportunity. And the harrowing Zika virus is no different. Investors are jumping into stocks focused on detecting or wiping out the virus.

Luminex Corporation Receives FDA Clearance And CE-IVD Mark For The ARIES M1 System

Luminex Corporation Receives FDA Clearance And CE-IVD Mark For The ARIES M1 System

ARIES platform extension provides the significant benefits of ARIES for clinical labs with lower throughput requirements

Luminex To Highlight Latest Additions To Product Portfolio At The 2016 Clinical Virology Symposium

Luminex To Highlight Latest Additions To Product Portfolio At The 2016 Clinical Virology Symposium

Luminex products highlighted in more than 20 poster presentations, and workshop featuring 3 ARIES customers discussing results from their labs

Commit To Purchase Luminex Corp At $20, Earn 15.8% Annualized Using Options

Commit To Purchase Luminex Corp At $20, Earn 15.8% Annualized Using Options

Investors considering a purchase of Luminex Corp shares, but cautious about paying the going market price of $20.04/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $20 strike, which has a bid at the time of this writing of $1.65.

Luminex Corporation Receives FDA Clearance And CE Mark For SYNCT Software

Luminex Corporation Receives FDA Clearance And CE Mark For SYNCT Software

Single Interface for Luminex Data Provides Lab Directors Streamlined Workflow, Improved Data Management, and the Ability to Easily Add New Functionality with Minimal Validation